Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Oramed Pharmaceuticals

  • Nadav Kidron , Oramed Pharmaceuticals

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

  • Date:Tuesday, February 12
  • Time:1:45 PM - 2:00 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:23361
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Update investors and others about Oramed's platform technology and clinical studies on oral insulin
  • Company Website:www.oramed.com
  • Company HQ City:New York
  • Company HQ State:New York
  • Company HQ Country:United States
  • Ticker:ORMP
  • Exchange:Nasdaq
  • Main Therapeutic Focus:Platform for Therapeutics
  • Lead Product in Development:Oral Insulin
  • Development Phase of Primary Product:Phase II
Speakers
Nadav Kidron
Oramed Pharmaceuticals
Back